Medicines and Risk/Benefit Decisions

ided the opportunity for a group of experts from the Industry, academia and the regulatory authorities to meet and discuss ways and means by which risk benefit decisions are made during the various stages of drug development. Risks from medicines must always be viewed in relation to the risks from untreated diseases.